Anixa Biosciences, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended October 31, 2023. Although the request identifies 2023 Q4, this filing reports annual results; it does not provide standalone fourth-quarter financial results. Financial statements are audited and prepared under U.S. GAAP.
Business context
Anixa is a pre-revenue biotechnology company focused on cancer vaccines and cell therapy. Its main programs are a Phase 1 breast cancer vaccine, ovarian cancer vaccine development, and Phase 1 ovarian cancer CAR-T therapy through subsidiary Certainty Therapeutics. The company paused its COVID-19 antiviral program in March 2023. Legacy patent licensing generated the year’s only revenue; no revenue has been generated from its vaccine or therapeutic programs.
Financial highlights
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0.210 million | $0 |
| Research and development expense | $4.769 million | $6.703 million |
| General and administrative expense | $6.291 million | $7.172 million |
| Operating loss | $11.011 million | $13.875 million |
| Net loss | $9.930 million | $13.771 million |
| Net loss attributable to common stockholders | $9.811 million | $13.595 million |
| Basic and diluted loss per share | $0.32 | $0.45 |
| Net cash used in operating activities | $6.209 million | $6.492 million |
FY2023 revenue was a one-time licensing payment for encrypted audio/video conference-calling technology. Revenue is too limited for a meaningful operating-margin comparison. Interest income rose to $1.081 million from $0.104 million. The smaller net loss reflected lower operating expenses and higher interest income; it does not indicate product revenue or profitability.
Liquidity and obligations: Cash and cash equivalents were $0.915 million and short-term investments were $22.929 million at October 31, 2023, totaling $23.844 million, down from $29.687 million a year earlier. Working capital was $23.328 million. Total liabilities were $2.151 million, primarily accounts payable, accrued expenses, and lease liabilities; the filing reports no significant off-balance-sheet arrangements. Future minimum office lease payments were $0.202 million. License commitments for FY2024 were approximately $0.070 million. Potential future payments under breast-vaccine research and development agreements were approximately $3.5 million, potentially over as many as five years.
Material changes and operating developments
- R&D expense declined $1.934 million year over year, including lower COVID-19 program spending after its March 2023 pause. Cancer-vaccine R&D rose by approximately $0.563 million, while CAR-T and ovarian-vaccine spending declined.
- All three expanded breast-vaccine Phase 1a dose cohorts had completed vaccination by August 2023. Preliminary immune data presented in December showed antigen-specific T-cell responses at all dose levels tested to date. Further dose cohorts and Phase 1b and Phase 1c participants were being vaccinated or enrolled.
- Three patients had received the same initial dose in the ovarian CAR-T Phase 1 study by August 2023; treatment appeared well tolerated in those patients. Management anticipated starting the next, three-times-higher-dose cohort in the first calendar quarter of 2024.
- The NCI PREVENT program is supporting most preclinical development and IND-enabling work for the ovarian cancer vaccine, with no material company expenditure expected for that work.
Outlook, risks and unusual items
As of January 16, 2024, management believed available cash, investments, and expected cash flows would fund activities for at least 12 months. This is an estimate, not a guarantee; management cautioned that actual cash needs may differ and additional financing may be required. The company reported an effective at-the-market offering program with up to $100 million available as of October 31, 2023 and said it sold no shares under the program during FY2023. Equity financing could dilute shareholders.
Key risks include the early clinical stage and uncertain safety or efficacy of candidates, trial enrollment and timing, reliance on research and clinical partners, manufacturing and regulatory challenges, dependence on licensed intellectual property, competition, and the possibility of further funding needs. The company reported an accumulated deficit of $228.196 million and expects continued losses. No material pending legal proceedings against the company were reported. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not attest to internal controls under the company’s smaller-reporting-company exemption.
Important facts for investors to verify
- Subsequent clinical-trial enrollment, dose escalation, safety findings, and whether preliminary immune-response observations translate into meaningful clinical outcomes.
- Cash and investment balances, operating cash burn, and management’s stated minimum 12-month funding outlook against actual spending and financing activity.
- Potential dilution from the ATM program, outstanding equity awards, and future capital raising.
- Timing and amount of potential research-contract payments, license milestones, and other program costs.
- That FY2023 revenue was a one-time legacy licensing payment and that the filing provides no standalone Q4 results.